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Introduction
Septic shock is a systemic response to infection which 
is accompanied with tissue hypoperfusion. It does not 
respond to fluid therapy and eventually leads to organ 
dysfunction and death (1). Septic shock is considered as 
an emergency. It is noteworthy that the tenth cause of 
death in the United States is septic shock (2). Many efforts 
are done to improve the prognosis and reduce mortality 
due to septic shock. Antimicrobial drugs are considered 
as the main treatment. In addition, vasopressin, anti-
inflammatory drugs, gram-negative bacteria endotoxin 
neutralizing materials and anticoagulant therapy and 
supportive cares are used as additives to prevent damage 
to other organs. One of the treatments under investigation 
is the use of corticosteroids in the management of septic 
shock (3). Despite numerous studies on using steroids 
in the treatment of septic shock, controversies still exist 
(4). It is proven that a high dose of corticosteroids has 
harmful effects in the management of septic shock (5). 
However, lots of debates for using low dose corticosteroids 
in refractory septic shock exist (6). These controversies 
are often about the type of steroid, dose and duration of 
administration.
Incidence of adrenal insufficiency in septic shock is about 
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Abstract
Objective: Septic shock is a response to infection and tissue hypoperfusion which does not 
respond to fluid therapy and eventually leads to organ dysfunction. Aggressive treatment 
of a broad-spectrum antimicrobial and supportive measures are the cornerstones of 
successful treatment. In addition to the main treatment, there are adjunctive therapies. 
Steroids are one of the treatments which have been studied in the management of 
refractory septic shock. Despite numerous studies on the role of steroids in the mortality 
of severe sepsis and septic shock, still lots of controversies exist. These conflicts are often 
about the steroid dose and duration of administration.
Methods: This was a prospective, randomized-controlled, two-group assignment study. 
Patients referred to Imam Reza (AS) hospital in Mashhad who had refractory septic shock 
criteria were randomly divided into two groups: 80 patients were included in each group. 
After obtaining the baseline cortisol level and cosyntropin test, one group was treated 
with intravenous hydrocortisone, and the other group was treated with placebo. The 
response to hydrocortisone, the return of shock duration, and mortality at 28 days were 
investigated.  The data were analyzed using SPSS version 16. For the normally distributed 
variables, a t test was used for comparisons. Concerning qualitative variables, the chi-
square test or Fisher exact test were applied accordingly.
Results: The return of shock duration and mortality in intervention group patients was 
more than control group, but it was not statistically significant. 
Conclusion: Despite numerous studies in this field, there are various outcomes (mortality 
rate, rate of return of shock, time of return of shock). These differences can be attributed 
to high degree of heterogeneity. Perhaps considering the underlying disease and more 
differentiation could change the return of shock and mortality rate.
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50%. Adrenal insufficiency means partial or no systemic 
response to cortisol which is called CIRCI (critical illness 
related corticosteroid insufficiency) (7). The adrenal 
insufficiency in septic shock means level of serum 
cortisol less than 9 µg/dL after administration of 250 µg 
adrenocorticotropic hormone (ACTH) or random serum 
cortisol level less than 10 µg/dL (8). It was demonstrated 
that there is a relationship between cortisol level and 
response to ACTH stimulation test and the survival rate 
of septic shock in patients (9).
In a randomized controlled trial (RCT) study, intervention 
group received 100 mg hydrocortisone every 8 hours for 5 
days and the control group received placebo. The mortality 
rate and return of shock were statistically significant in 
intervention group (10). In a RCT conducted in Turkey 
intravenous prednisolone was used. In this study, there 
was no relationship between age, underlying disease, 
corticosteroid treatment, serum cortisol, response to 
cosyntropin and finally mortality (11). In another RCT 
study 50 mg hydrocortisone followed by 0.18 mg/kg/h 
was given to the intervention group. Mortality rates, 
return of the shock, and response to cosyntropin test 
was not different in two groups (12). In an RCT study in 
2008, 50 mg intravenous hydrocortisone was used every 
6 hours for 5 days. There was no significant difference in 
mortality in those who did not respond or responded to 
cosyntropin test in two groups in 28 days. Mortality also 
did not show a difference in two groups. Return of shock 
in patients receiving hydrocortisone happened faster than 
placebo and it was statistically significant, but return of 
shock rate was not significant (13). In another study, 28-
day mortality did not show significant difference between 
the intervention and placebo groups (14). There are still 
lots of debates for using low dose corticosteroid septic 
shock in the treatment of patients. For better treatment 
of refractory septic shock, we designed a study to evaluate 
the effect of low-dose hydrocortisone in mortality of 
septic shock.
Methods
This randomized, double-blind, clinical trial study was 
conducted in Imam Reza hospital (a referral hospital 
in the second most populated city of Iran) in Mashhad 
from August 2014 to April 2015. We enrolled (a) Patients 
>18 years old referred to Imam Reza (AS) hospital in 
Mashhad and (b) patients with septic shock criteria that 
did not respond to vasopressor therapy for more than 60 
minutes. We excluded (a) patients who had documented 
adrenal insufficiency before admission, (b) patients with 
tuberculosis, and (c) patients treated with ketoconazole or 
estrogen. 
This was a prospective, randomized-controlled, two-
group assignment study.
Using concealed envelopes marked in advance, study 
participants were randomized in a 1:1 ratio by simple 
method randomization following screening, fulfilling the 
inclusion criteria, and signing an informed consent form. 
In total, 160 patients were selected randomly. They were 
divided into study group (80 patients) and control group 
(80 patients). 
First, basal cortisol levels were evaluated in patients’ 
venous sample. Then 250 mg ACTH was administered 
intramuscularly. After 30-60 minutes, venous cortisol 
level was checked to evaluate the response to ACTH. 
Adrenal insufficiency means serum cortisol level less than 
9 µg/dL after administration of 250 µg ACTH or random 
serum cortisol level less than 10 µg/dL.
One group was treated with administration of 50 mg 
hydrocortisone intravenously every 6 hours and another 
group was treated with placebo (saline in the same 
volume) for 7 days. Then return of shock and mortality 
at 28 days in both groups were determined. Response 
to hydrocortisone is defined as no need to vasopressor 
therapy for at least 6 hours in patients with diagnosis of 
septic shock. 
The sample size was obtained based on Bollaert et al study 
(10), in terms of type I error (or α = 0.05). Also, to have 
90% power for comparing the mortality in 28 days in two 
groups, we had the maximum sample size of 80 patients 
in each group.
Analyzing the data was done by SPSS version 16. For 
normally distributed variables, a t test was used for 
comparisons. Concerning qualitative variables, the chi-
square test or Fisher exact test were applied. Spearman 
correlation was used for comparison of two non-normally 
distributed quantitative variables. A P value <0.05 was 
regarded as statistically significant.
Results
As it is demonstrated (Table 1), distribution of basic 
characteristics was normal. The most prevalent underline 
disease in intervention group was pulmonary disease and 
diabetes and in control group it was diabetes. The least 
prevalent disease belonged to liver disease in both control 
and intervention groups. In general, diabetes was the most 
common underlying disease (40%). Pulmonary diseases 
here included chronic obstructive pulmonary disease 
(COPD) and interstitial lung disease (ILD). Neurologic 
diseases encompassed history of cerebrovascular accidents 
and cerebral palsies and patients who were under the 
treatment of epilepsy. 
The difference was not significant in mortality in 
intervention group with cosyntropin positive and negative 
test (P = 0.259). The difference was not also significant in 
mortality in control group with cosyntropin positive and 
negative test (P = 0.597).
Outcome in intervention and control groups is 
demonstrated in Table 2. Mortality according to underline 
disease in intervention group and control group is 
illustrated in Table 3.
In general, there were significant differences in mortality 
rate in septic shock patients with and without diabetes 
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group with renal failure (P = 0.04). Patients with renal 
failure who received hydrocortisone had a higher 
significant mortality (Table 3). 
Discussion
In this study, we could not find any significant difference 
in 28-day mortality and return of shock in 7 days in 
intervention group and control group. Mortality in 
patients with positive cosyntropin test and negative 
cosyntropin test (in subgroups who had received or not 
received hydrocortisone) did not differ significantly. The 
results of this study have some similarities and differences 
with previous studies.
In the meta-analysis in 2014 in China, 28-day mortality 
did not differ significantly by administration of 
hydrocortisone. The return of the shock at 7 days in 
both groups was significant (P < 0.0001). In this meta-
analysis, secondary infection caused by hydrocortisone 
was also evaluated. In this study, hyperglycemia in two 
groups was significant (15). In a systemic review in 
2012, a statistically significant reduction in mortality was 
observed in intervention group. The return of the shock 
rate had no significant difference. But, duration time of 
shock return differed significantly (3.3 versus 5.8 days). 
The point in these articles was new septic shock in patient 
who received hydrocortisone (16). In a RCT in 2008, 50 
mg hydrocortisone was used every 6 hours. Mortality in 
hydrocortisone group was 3% more, but did not differ 
significantly. Mortality also did not differ in subgroups with 
and without response to cosyntropin test. In both groups, 
the rate of return of shock did not differ significantly. But 
in hydrocortisone group, the return of shock occurred 
faster (13). In a study on patients with refractory septic 
Table 1. Basic characteristic of intervention and control groups
Basic characteristic Intervention group
Control 
group P
Gender, No. (%) 0.749
Male 47 (58.8) 33 (41.3)
Female 45 (56.3) 35 (43.8)
Mean age 67.13±10.92 66.93 ±11.24 0.909
Response to cosyntropin 
test, No. (%) 44 (55) 42 (52.5) 0.751
Underline disease, No. (%)
Pulmonary disease 33 (41.33) 28 (35) 0.416
Hypertension 22 (27.5) 18 (22.5) 0.465
Diabetes 32 (40) 32 (40) >0.99
Renal failure 17 (21.3) 16 (20) 0.845
Malignancy 24 (30) 28 (35) 0.500
Heart failure 26 (32.5) 24 (30) 0.733
Neurologic disease 10 (12.5) 10 (12.5) >0.99
Liver failure 7 (8.8) 9 (11.3) 0.598
Table 2. Outcome in intervention and control groups
Outcome
Intervention group
No. (%)
Control group
No. (%)
P
Return of shock 27 (33.8) 20 (25) 0.224
Mortality 54 (67.5) 58 (72.5) 0.490
Table 3.  Mortality according to underline disease in intervention group and control group
Intervention group
No. (%)
P value
Control group
No. (%)
P value
Pulmonary disease
Patients with disease 23 (69.7)
0.752
24 (87.5)
0.052
Patients without disease 31 (66) 34 (65.4)
Hypertension
Patients with disease 15 (68.2)
0.936
12 (66.7)
0.529
Patients without disease 39 (67.2) 46 (74.2)
Diabetes
Patients with disease 28 (87.5)
0.002
30 (93.8)
0.001
Patients without disease 26 (54.2) 28 (58.3)
Renal failure
Patients with disease 15 (88.2)
0.04
14 (87.5)
0.133
Patients without disease 39 (61.9) 44 (68.8)
Malignancy
Patients with disease 19 (66.7)
0.917
19 (67.9)
0.495
Patients without disease 38 (67.9) 39 (75)
Heart failure 
Patients with disease 14 (53.8)
0.07
19 (79.2)
0.382
Patients without disease 40 (74.1) 39 (69.6)
Neurologic disease
Patients with disease 8 (80)
0.367
7 (70)
0.850
Patients without disease 46 (65.7) 51 (72.9)
Liver failure 
Patients with disease 7 (100)
0.055
8 (88.9)
0.242
Patients without disease 47 (64.4) 50 (70.4)
(P < 0.001), renal failure (P = 0.012) and liver failure 
(P = 0.029) (Table 4). 
Mortality had a statistically significant difference in 
patients with and without diabetes in both groups. 
Mortality also had a significant difference in intervention 
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shock which were given low dose of hydrocortisone, the 
mortality rate differed significantly (17). In a retrospective 
study on refractory septic shock with 28-day mortality of 
55%, they concluded that higher basal cortisol level was 
related with higher mortality and response to cosyntropin 
test did not relate to outcome (18). In the last version 
of international guidelines for management of severe 
sepsis and septic shock, there is no recommendation for 
hydrocortisone administration in septic shock. There 
is only recommendation for hydrocortisone when it is 
refractory to vasopressors (level 2c) (19).
In previous studies, type of steroid (methylprednisolone 
and hydrocortisone) and method of administration 
(divided doses versus infusion) did not alter the 
prognosis and mortality (11-13). In a study in China, 
slow intravenous infusion was compared with 
continuous intravenous infusion of hydrocortisone. It 
was demonstrated that continuous intravenous infusion 
could maintain metabolic balance and blood glucose 
levels. But there was no significant difference in 28-
day mortality (20). Currently, recent research show that 
patients with acute respiratory distress syndrome or burns 
or community-acquired pneumonia respond well to low 
dose hydrocortisone and it can reduce the morbidity rate 
(21). In a few studies, source of infection was considered 
and mortality was obtained according to the source. Low-
dose corticosteroid therapy was associated with reduced 
mortality in patients with refractory septic shock after 
emergency laparotomy of lower intestinal perforation (22). 
In patients with severe community-acquired pneumonia, 
the use of methylprednisolone decreased treatment failure 
in compare with placebo group (23). Maybe classification 
of septic shock according to the source of the infection 
Table 4. Mortality according to underline disease in total patients
Total 
patients
P
Pulmonary 
disease
Patients with disease 47 (77)
0.127
Patients without disease 65 (65.7)
Hypertension
Patients with disease 27 (67.5)
0.690
Patients without disease 85 (70.8)
Diabetes
Patients with disease 58 (90.6)
0.000
Patients without disease 54 (56.3)
Renal failure
Patients with disease 29 (87.9)
0.012
Patients without disease 83 (65.4)
Malignancy
Patients with disease 35 (67.3)
0.606
Patients without disease 77 (71.3)
Heart failure 
Patients with disease 33 (66)
0.457
Patients without disease 79 (71.8)
Neurologic 
disease
Patients with disease 15 (75)
0.602
Patients without disease 97 (69.3)
Liver failure 
Patients with disease 15 (93.8)
0.029
Patients without disease 97 (67.4)
and application of steroids could lead to better results.
In our study mortality rate was 70%. Hydrocortisone group 
had a slightly lower mortality, but it was not significant 
(67.5% versus 72.5%). Return of shock in intervention 
group was higher (33.8% versus 25%). This difference was 
not significant. The rate of response to cosyntropin test 
was more in patients who received hydrocortisone, but it 
was not significant. Higher response to cosyntropin test 
does mean that adrenal insufficiency was less common 
in hydrocortisone group, therefore, fewer patients needs 
hydrocortisone in this group. Maybe this is the reason of 
no difference in mortality in two groups. 
In some studies, complications of hydrocortisone such as 
gastrointestinal bleeding, new infection, hyperglycemia 
and hypernatremia were taken into account. In our study, 
we considered underlying diseases (Table 3). The most 
common underline disease in intervention group was 
pulmonary disease and in control group it was diabetes. 
The least common in both groups was liver failure. Few 
studies considered underline disease and its relationships 
to death. In a systemic review and meta-analysis which 
was done in 2015, a total of 35 articles were assessed. It 
included 4682 patients and there was no relation between 
steroid doses and mortality (24). Death in patients with 
and without diabetes had a significant difference. It can 
be concluded that patients with septic shock who had 
diabetes have worst prognosis. Mortality in patients with 
and without renal failure and liver failure was significant. 
Renal failure patients in intervention group had a 
statistically significant difference in mortality. It can be 
concluded that in a renal failure patient with septic shock, 
hydrocortisone is not suitable. More study is needed to 
determine the role of underline disease in prognosis of 
septic shock. 
Conclusion
Despite numerous studies in different parts of the world, 
different results have been obtained (mortality rate, return 
of shock rate and duration of shock). These diversities 
could be attributed to high heterogeneity of groups. It is 
recommended that in future studies underline disease 
or source of the infection be considered and indices be 
evaluated in more differentiated groups.
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